Severity: Warning
Message: file_get_contents(https://...@pubfacts.com&api_key=b8daa3ad693db53b1410957c26c9a51b4908&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 176
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 176
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 250
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 1034
Function: getPubMedXML
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3152
Function: GetPubMedArticleOutput_2016
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
A 63-year-old woman underwent surgery for Stage IV cancer of the ascending colon with multiple lymph node metastases. The pathological diagnosis was neuroendocrine carcinoma. Following first-line chemotherapy, the patient presented clinically with progressive disease (PD). Second-line chemotherapy with bevacizumab/Leucovorin and 5-fluorouracil with oxaliplatin (FOLFOX4) was effective and a partial response (PR) was achieved after 7 courses of therapy, as determined by computed tomography (CT) examination. Neuroendocrine carcinoma is known to be extremely malignant; however, this case suggests that chemotherapy with bevacizumab may improve the prognosis of this disease.
Download full-text PDF |
Source |
---|
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!